HTA-Information Service Rapid Reviews
Since 2023, the Austrian Institute for Health Technology Assessment (AIHTA) is supporting the decisions of Austrian social insurance funds with short evidence syntheses as well as those of hospital providers with factsheets on new, expensive medicines. The aim is to support these decisions on medical services with evidence. The best available evidence from current reviews and clinical trials is summarised.
HTA -Information Service No. 015
Massive parallel sequencing – technologies for high-throughput analysis of genetic-genomic data sets
HTA-Information Service Review No. 014
Skin cancer prevention: Guideline recommendations for primary and secondary prevention
HTA-Information Service Review No. 013
CAR-based immunotherapy with a focus on CAR-NK cells
HTA-Information Service Review No. 012
Use of telepathology for intraoperative frozen section examination
HTA-Information Service Review No. 011
Calcitonin gene-related peptide antagonists for the prevention of migraine - summary of the BAG /RACS HTA report 2023
HTA -Information Service Review No. 010
Biomarkers in Parkinson's Disease
HTA -Information Service Review No. 009
Liposuction for the removal of subcutaneous (large) lipomas
HTA-Information Service Rapid Review No. 008
Endovenous laser therapy for varicose veins in the lower extremities
HTA-Information Service Rapid Review No. 007
Autologous fat grafting in osteoarthritis
HTA-Information Service Rapid Review No. 006
Myopia control spectacle lenses for children and adolescents
HTA-Information Service Rapid Review No. 005
Robot-assisted rehabilitation for incomplete spinal cord injury
HTA-Information Service Rapid Review No. 004
Biomarkers in Alzheimer's Disease
HTA-Information Service Rapid Review No. 003
Radiofrequency denervation for chronic lumbar or cervical spine pain
HTA-Information Service Rapid Review No. 002
Extracorporeal shock wave therapy for orthopaedic indications
HTA-Information Service Rapid Review No. 001
iv Immunoglobulins (IgVena) in recurrent in vitro fertilisation implantation failure and/or recurrent pregnancy loss